Skip to main content
Livermore
Livermore
ZHEN

Sierra Oncology, Inc.

SRRADelisted Jul 1, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001290149

Sierra Oncology, Inc. was delisted on Jul 1, 2022; its insiders filed their last Form 4 on Jul 1, 2022; 109 institutions reported holding it in 13F filings for Q2 2022, worth $1.23B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Sierra Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Sierra Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Sierra Oncology, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Vivo Ventures Fund VII, L.P.Director, 10% Owner0IndirectJul 1, 20220
Vivo Ventures VII Affiliates Fund, L.P.Director, 10% Owner0IndirectJul 1, 20220
Vivo Ventures VII, LLCDirector, 10% Owner0IndirectJul 1, 20220
Vivo Opportunity, LLCDirector, 10% Owner0IndirectJul 1, 20220
Vivo Capital Fund IX, L.P.Director, 10% Owner0IndirectJul 1, 20220
Vivo Capital IX, LLCDirector, 10% Owner0IndirectJul 1, 20220
Vivo Opportunity Fund Holdings, L.P.Director, 10% Owner0IndirectJul 1, 20220
OrbiMed Advisors LLCDirector, 10% Owner0IndirectJul 1, 20220
OrbiMed Capital LLCDirector, 10% Owner0IndirectJul 1, 20220
OrbiMed Capital GP VII LLCDirector, 10% Owner0IndirectJul 1, 20220
OrbiMed Genesis GP LLCDirector, 10% Owner0IndirectJul 1, 20220
Thomson Mary ChristinaGeneral Counsel0Jul 1, 20220
Pelzer RobertDirector–Jul 1, 20220
Cooper Jeffrey HDirector–Jul 1, 20220
Collard Craig ADirector0Jul 1, 20220
Allen Andrew RDirector, 10% Owner0Jul 1, 20220
Dilly Stephen GeorgeCEO and President0Jul 1, 20220
Aggarwal GauravDirector0IndirectJul 1, 20220
Jagpal SukhiChief Financial Officer–Jul 1, 20220
Erbez GeorgiaDirector–Jul 1, 20220
Klencke BarbaraChief Medical Officer0IndirectJul 1, 20220
Sinclair AndrewDirector0IndirectJul 1, 20220
Ashiya MonaDirector, 10% Owner0IndirectJul 1, 20220
Turner William D.Chief Reg & Tech Ops Officer0Jul 1, 20220
Norrett KevinChief Business Officer–Jul 1, 20220
Oliger Christy J.Director–Jul 1, 20220
Enright Patrick G10% Owner8,015IndirectApr 29, 20220
Tammenoms Bakker Juliet10% Owner8,015IndirectApr 29, 20220
Longitude Venture Partners III, L.P.10% Owner8,015IndirectApr 29, 20220
Longitude Capital Partners III, LLC10% Owner8,015IndirectApr 29, 20220
Longitude Prime Partners, LLC10% Owner8,015IndirectApr 29, 20220
Longitude Prime Fund, L.P.10% Owner8,015IndirectApr 29, 20220
Richardson JoshuaDirector, 10% Owner175,000IndirectFeb 2, 20220
Abingworth LLP10% Owner1,314,127IndirectFeb 1, 20220
Vivo Opportunity Fund, L.P.10% Owner2,735,853IndirectJan 31, 20220
Kowalski MarkChief, Research & Early Dev–Jan 28, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 24, 2021 (view filing)Nov 23-241 dayCollard Craig ADirectorPPurchase+13.5K$23.03+$310.9KNew position13.5K after2 lots
Jan 28, 2022 (view filing)Jan 262 daysTurner William D.Chief Reg & Tech Ops OfficerSSale−5.00K$27.05−$135.3K−100.0%0 after
Jan 28, 2022 (view filing)Jan 262 daysThomson Mary ChristinaGeneral Counsel & SecretarySSale−2.00K$29.00−$58.0K−100.0%0 after
Jan 31, 2022 (view filing)Jan 31Same dayAggarwal GauravDirector, 10% OwnerPPurchase+800.0K$27.00+$21.6M+41.3%2.74M after
Jan 31, 2022 (view filing)9:30 PM ETJan 31Same dayVivo Ventures Fund VII, L.P. and 6 others10% OwnerPPurchase+800.0K$27.00+$21.6M+41.3%2.74M afterDuplicate filing
Feb 1, 2022 (view filing)Jan 311 dayAbingworth LLP10% OwnerPPurchaseCommon Stock, $0.001 par value+150.0K$27.00+$4.05M+12.9%1.31M after
Feb 1, 2022 (view filing)Jan 311 daySinclair AndrewDirectorPPurchaseCommon Stock, $0.001 par value+150.0K$27.00+$4.05M+12.9%1.31M afterDuplicate filing
Feb 2, 2022 (view filing)Feb 2Same dayRichardson JoshuaDirector, 10% OwnerPPurchase+175.0K$27.00+$4.72MNew position175.0K after
Feb 2, 2022 (view filing)9:25 PM ETFeb 2Same dayEnright Patrick G and 5 others10% OwnerPPurchase+175.0K$27.00+$4.72MNew position175.0K afterDuplicate filing
Feb 4, 2022 (view filing)Feb 4Same dayThomson Mary ChristinaGeneral Counsel, CCO & Sec'ySSale−2.00K$29.78−$59.6K−100.0%0 after
Feb 8, 2022 (view filing)Feb 71 dayTurner William D.Chief Reg & Tech Ops OfficerSSale−10.0K$32.32−$323.2K−100.0%0 after
Mar 4, 2022 (view filing)Mar 4Same dayThomson Mary ChristinaGeneral Counsel, CCO & Sec'ySSale−2.00K$30.60−$61.2K−100.0%0 after
Mar 17, 2022 (view filing)Mar 17Same dayTurner William D.Chief Reg & Tech Ops OfficerSSale−3.45K$37.06−$128.0K−100.0%0 after
Mar 22, 2022 (view filing)Mar 184 daysTurner William D.Chief Reg & Tech Ops OfficerSSale−100$37.05−$3.71K−100.0%0 after
Apr 4, 2022 (view filing)Apr 4Same dayThomson Mary ChristinaGeneral Counsel, CCO & Sec'ySSale−2.00K$35.14−$70.3K−100.0%0 after
Apr 7, 2022 (view filing)Apr 5-62 daysTurner William D.Chief Reg & Tech Ops OfficerSSale−6.45K$37.25−$240.1K−100.0%0 after2 lots